Trade Fresenius SE & Co KGaA - FRE CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.12
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.017307 %(-€3.46)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.01731%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.004915 %(-€0.98)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.00492%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Germany
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.017307 %
  (-€3.46)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.004915 %
  (-€0.98)

Key Stats

• Prev. Close: 47.76
• Open: 47.55
• 1-Year Change: 4.44%
• Day's Range: 47.02 - 47.57

Trade Fresenius SE & Co KGaA - FRE

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Fresenius SE & Co KGaA revenues increased 3% to EUR37.52B. Net income increased 7% to EUR1.82B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from EUR3.06 to EUR3.26.

Equity composition

11/2005, Rights Issue, 2 new shares for every 9 shares held @ EUR 93 (Factor: 1.025064). 02/2007, Complex capital change (Factor: 3). 07/2007, Company name changed from Fresenius AG. 8/2014, Scrip Issue, 2 new share for every 1 share held (Factor: 3).